ArticleReports of biochemistry & molecular biology2025
Reduced Oral Squamous Cell Carcinoma Risk Associated with
Article in Reports of biochemistry & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) represents the predominant form of cancer affecting the oral cavity, accounting for more than 90% of all oral malignancies. Despite advancements in treatment, the five-year survival rate has remains relatively unchanged, primarily due to late-stage diagnosis. This study aimed to evaluate the genetic variation in Methods: A cross-sectional case-control study was performed, including a total of 102 patients diagnosed with OSCC and 100 healthy individuals serving as controls. Genotyping of the Results: The predominant genotype observed in both OSCC patients and healthy controls was the CT genotype, with respective frequencies of 45.1% and 55%. The least frequent genotype in both groups was TT, with frequencies of 12.7% in patients and 17% in controls. Most patients were in tumor grade 1 (70.96%) and tumor stage III (35.8%). Among the patients, 53.3% showed lymph node involvement. No statistically significant associations were observed between clinicopathological features and genotypes (P>0.05). The allele frequencies of MLH1 rs63749795 did not differ significantly between patients and controls. However, the rs63749795 polymorphism was associated with reduced OSCC susceptibility under the dominant genetic model (OR = 0.53, 95% CI = 0.29-0.96, P = 0.03 for CT+TT vs. CC genotype). Conclusions: The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.